Correction regarding data on blinatumomab-associated seizures Max S. Topp [3] [4] [5] , this range refers to the total frequencies of all grade ≥3 neurological adverse events combined, including not only seizures, but also encephalopathy, confusion, and cerebellar symptoms. Across several studies involving adults with relapsed and/or refractory B-cell acute lymphoblastic leukaemia (B-ALL) who received blinatumomab, seizures of any grade were reported in 2.1-8.3% of 246 patients in total: one of 21 patients with persistence or relapse of minimal residual disease (4.8%) had a grade 3 seizure in an early phase II trial 3 ; three of 36 patients (8.3%) had epileptic seizures or convulsions leading to treatment interruption in the dose-finding phase II study 4 ; and four of 189 patients (2.1%) had convulsions in the confirmatory multicentre phase II trial 5 . Among the patients treated with blinatumomab in clinical trials, most of the neurological adverse events observed have been low-grade tremors and dizziness [3] [4] [5] . More-serious neurological events, such as seizures and encephalopathy, have been the most-common reasons for treatment interruptions (frequency of 15-17%) and discontinuations (frequency of 4.8%) [3] [4] [5] , but patients have generally responded well to interventional therapy for these toxicities. Indeed, these adverse events have predominantly been limi ted in duration and primarily resolved with treatment interruption and/or standard anticonvulsive therapies, and most of the patients were subsequently able to resume blinatumomab therapy [3] [4] [5] . Given the few treatment options currently available for relapsed and/or refractory B-ALL, we feel that accurately reporting the blinatumomab-related seizure rate is pertinent, in order to better inform appropriate treatment decisions. 
